A new ligand for the peroxisome proliferator-activated receptor-γ (PPAR-γ), GW7845, inhibits rat mammary carcinogenesis

Cancer Research

Volumn 59, Issue 22, 1999, Pages 5671-5673

  Suh, Nanjoo ^a   Wang, Yongping ^a   Williams, Charlotte R ^a   Risingsong, Renee ^a   Gilmer, Tona ^b   Willson, Timothy M ^b   Sporn, Michael B ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 CARBOXY 2 [4 [2 (5 METHYL 2 PHENYL 4 OXAZOLYL)ETHOXY]PHENYL]ETHYLAMINO]BENZOIC ACID METHYL ESTER; METHYLNITROSOUREA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; HUMAN; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR VOLUME;

ANIMALS; ANTICARCINOGENIC AGENTS; CARCINOGENS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; LIGANDS; MAMMARY NEOPLASMS, EXPERIMENTAL; METHYLNITROSOUREA; OXAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TAMOXIFEN; TRANSCRIPTION FACTORS; TYROSINE;

EID: 0033571433     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Landis, S. H., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1999. CA Cancer J. Clin., 49: 8-64, 1999.
2. Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., Daly, M., Wieand, S., Tan-Chiu, E., Ford, L., and Wolmark, N. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J. Natl. Cancer Inst., 90: 1371-1388, 1998.
3. Cummings, S. R., Eckert, S., Krueger, K. A., Grady, D., Powles, T. J., Cauley, J. A., Norton, L., Nickelsen T., Bjarnason, N. H., Morrow, M., Lippman, M. E., Black, D., Glusman, J. E., Costa, A., and Jordan, V. C. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA, 281: 2189-2197, 1999.
4. Veronesi, U., De Palo, G., Marubini, E., Costa, A., Formelli, F., Mariani, L., Decensi, A., Camerini, T., Del Turco, M. R., Di Mauro, M. G., Muraca, M. G., Del Vecchio, M., Pinto, C., D'Aiuto, G., Boni, C., Campa, T., Magni, A., Miceli, R., Perloff, M., Malone, W. F., and Sporn, M. B. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J. Natl. Cancer Inst., 91: 1847-1856, 1999.
5. Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schutz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., and Evans, R. M. The nuclear receptor superfamily: the second decade. Cell, 83: 835-839, 1995.
6. Kliewer, S. A., and Willson, T. M. The nuclear receptor PPARγ-bigger than fat. Curr. Opin. Genet. Dev., 8: 576-581, 1998.
7. Kliewer, S. A., Lehmann, J. M., and Willson, T. M. Orphan nuclear receptors: shifting endocrinology into reverse. Science (Washington DC), 284: 757-760, 1999.
8. Kliewer, S. A., Umesono, K., Noonan, D. J., Heyman, R. A., and Evans, R. M. Convergence of 9-cis retinoic acid and peroxisome proliferator signaling pathways through heterodimer formation of their receptors. Nature (Lond.), 358: 771-774, 1992.
9. Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., and Kliewer, S. A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J. Biol. Chem., 270: 12953-12956, 1995.
10. Spiegelman, B. M. PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes, 47: 507-514, 1998.
11. Xu, H. E., Lambert, M. H., Montana, V. G., Parks, D. J., Blanchard, S. G., Brown, P. J., Stembach. D. D., Lehmann, J. M., Wisely, G. B., Willson, T. M., Kliewer, S. A., and Milburn, M. V. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol. Cell, 3: 397-403, 1999.
12. Rose, D. P. Dietary fatty acids and cancer. Am. J. Clin. Nutr., 66: 998S-1003S, 1997.
13. Ip, C. Review of the effects of trans fatty acids, oleic acid, n-3 polyunsaturated fatty acids, and conjugated linoleic acid on mammary carcinogenesis in animals. Am. J. Clin. Nutr., 66: 1523S-1529S, 1997.
14. Willett, W. C. Specific fatty acids and risks of breast and prostate cancer: dietary intake. Am. J. Clin. Nutr., 66: 1557S-1563S, 1997.
15. Mueller, E., Sarraf, P., Tontonoz, P., Evans, R. M., Martin, K. J., Zhang, M., Fletcher, C., Singer, S., and Spiegelman, B. M. Terminal differentiation of human breast cancer through PPARγ. Mol. Cell, 1: 465-470, 1998.
16. Elstner, E., Müller, C., Koshizuka, K., Williamson, E. A., Park, D., Asou, H., Shintaku, P., Said, J. W., Heber, D., and Koeffler, H. P. Ligands for peroxisome proliferator-activated receptorγ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc. Natl. Acad. Sci. U S A, 95: 8806-8811, 1998.
17. Brockman, J. A., Gupta, R. A., and DuBois, R. N. Activation of PPARγ leads to inhibition of anchorage independent growth of human colorectal cancer cells. Gastroenterology, 115: 1049-1055, 1998.
18. Tontonoz, P., Singer, S., Forman, B. M., Sarraf, P., Fletcher, J. A., Fletcher, C. D., Brun, R. P., Mueller, E., Altiok, S., Oppenheim, H., Evans, R. M., and Spiegelman, B. M. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor. Proc. Natl. Acad. Sci. U S A, 94: 237-241, 1997.
19. Demetri, G. D., Fletcher, C. D., Mueller, E., Sarraf, P., Naujoks, R., Campbell, N., Spiegelman, B. M., and Singer, S. Induction of solid tumor differentiation by the PPARγ ligand troglitazone in patients with liposarcoma. Proc. Natl. Acad. Sci. U S A, 95: 3951-3956, 1999.
20. Sarraf, P., Mueller, E., Jones, D., King, F. J., DeAngelo, D. J., Partridge, J. B., Holden, S. A., Chen, L. B., Singer, S., Fletcher, C., and Spiegelman, B. M. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat. Med., 4: 1046-1052, 1998.
21. Lefebvre, A. M., Chen, I., Desreumaux, P., Najib, J., Fruchart, J. C., Geboes, K., Briggs, M., Heyman, R., and Auwerx, J. Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APC-Min/+ mice. Nat. Med., 4: 1053-1057, 1998.
22. Saez, E., Tontonoz, P., Nelson, M. C., Alvarez, J. G., Ming, U. T., Baird, S. M., Thomazy, V. A., and Evans, R. M. Activators of the nuclear receptor PPARγ enhance colon polyp formation. Nat. Med., 4: 1058-1061, 1998.
23. Gelman, L., Fruchart, J-C., and Auwerx, J. An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer. Cell. Mol. Life Sci., 55: 932-943, 1999.
24. Cobb, J. E., Blanchard, S. G., Boswell, E. G., Brown, K. K., Charifson, P. S., Cooper, J. P., Collins, J. L., Dezube, M., Henke, B. R., Hull-Ryde, E. A., Lake, D. H., Lenhard, J. M., Oliver, W., Jr., Oplinger, J., Pentti, M., Parks, D. J., Plunket, K. D., and Tong, W. Q. N-(2-Benzoylphenyl)-L-tyrosine PPARγ agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent. J. Med. Chem., 41: 5055-5069, 1998.
25. Suh, N., Wang, Y., Honda, T., Gribble, G. W., Dmitrovsky, E., Hickey, W. F., Maue, R. A., Place, A. E., Porter, D. M., Spinella, M. J., Williams, C. R., Wu, G., Dannenberg, A. J., Flanders, K. C., Letterio, J. J., Mangelsdorf, D. J., Nguyen, L., Porter, W. W., Ren, R. F., Roberts, A. B., Roche, N. S., Subbaramaiah, K., and Sporn, M. B. A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity. Cancer Res., 59: 336-341, 1999.
26. Thompson, H. J., McGinley, J. N., Rothhammer, K., and Singh, M. Rapid induction of mammary intraductal proliferations, ductal carcinoma in situ and carcinomas by the injection of sexually immature female rats with 1-methyl-1-nitrosourea. Carcinogenesis (Lond.), 16: 2407-2411, 1995.
27. Anzano, M. A., Smith, J. M., Uskokovic, M. R., Peer, C. W., Mullen, L. T., Letterio, J. J., Welsh, M. C., Shrader, M. W., Logsdon, D. L., Driver, C. L., Brown, C. C., Roberts, A. B., and Sporn, M. B. 1α,25-Dihydroxy-16-ene-23-yne-26.27-hexafluorocholecalciferol (Ro24-5531), a new deltanoid (vitamin D analogue) for prevention of breast career in the rat. Cancer Res., 54: 1653-1656, 1994.
28. Gottardis, M. M., and Jordan, V. C. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res., 47: 4020-4024, 1987.